NOVONIX Ltd Files Form 6-K with ASX Announcement
Ticker: NVNXF · Form: 6-K · Filed: Sep 11, 2024 · CIK: 1859795
Sentiment: neutral
Topics: reporting, international, asx-announcement
Related Tickers: NVX
TL;DR
NOVONIX filed a 6-K with an ASX announcement, check it for updates.
AI Summary
NOVONIX Limited filed a Form 6-K on September 11, 2024, reporting for the month of September 2024. The filing includes an Exhibit 99.1, which is an ASX announcement. The company is incorporated in Australia and its principal executive office is located in Brisbane.
Why It Matters
This filing indicates ongoing reporting activity for NOVONIX Ltd, providing updates to investors through an ASX announcement.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves as a cover for an ASX announcement, with no immediate indication of significant financial or operational changes.
Key Players & Entities
- NOVONIX Limited (company) — Registrant
- 0000950170-24-105585 (filing_id) — Accession Number
- September 11, 2024 (date) — Filing Date
- Brisbane, QLD 4000 Australia (location) — Principal Executive Office
- Exhibit 99.1 (document) — Included Exhibit
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information to the SEC that NOVONIX Limited has made or will make public, is required to file with the Australian Securities Exchange (ASX), or is required to distribute to its security holders, as indicated by the inclusion of Exhibit 99.1, an ASX announcement.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on September 11, 2024.
Where is NOVONIX Limited's principal executive office located?
NOVONIX Limited's principal executive office is located at Level 38, 71 Eagle Street, Brisbane, QLD 4000, Australia.
What type of annual report does NOVONIX Limited file?
NOVONIX Limited files its annual reports under cover of Form 20-F.
What is included as an exhibit in this filing?
Exhibit 99.1, an ASX announcement, is included as part of this filing.
Filing Stats: 205 words · 1 min read · ~1 pages · Grade level 12.7 · Accepted 2024-09-11 17:19:04
Filing Documents
- nvx-6k-sept-24-09-10_mtd.htm (6-K) — 19KB
- nvx-ex99_1.htm (EX-99.1) — 588KB
- nvx-ex99_2.htm (EX-99.2) — 16KB
- img58969013_0.jpg (GRAPHIC) — 96KB
- img58969013_1.jpg (GRAPHIC) — 9KB
- img58969013_2.jpg (GRAPHIC) — 96KB
- img58969013_3.jpg (GRAPHIC) — 24KB
- img58969013_4.jpg (GRAPHIC) — 1230KB
- img58969013_5.jpg (GRAPHIC) — 971KB
- img58969013_6.jpg (GRAPHIC) — 398KB
- img58969013_7.jpg (GRAPHIC) — 807KB
- img58969013_8.jpg (GRAPHIC) — 889KB
- img59892534_0.jpg (GRAPHIC) — 75KB
- img59892534_1.jpg (GRAPHIC) — 542KB
- img59892534_2.jpg (GRAPHIC) — 240KB
- img59892534_3.jpg (GRAPHIC) — 233KB
- img59892534_4.jpg (GRAPHIC) — 273KB
- img59892534_5.jpg (GRAPHIC) — 268KB
- img59892534_6.jpg (GRAPHIC) — 96KB
- img59892534_7.jpg (GRAPHIC) — 187KB
- img59892534_8.jpg (GRAPHIC) — 95KB
- img59892534_9.jpg (GRAPHIC) — 270KB
- img59892534_10.jpg (GRAPHIC) — 239KB
- img59892534_11.jpg (GRAPHIC) — 260KB
- img59892534_12.jpg (GRAPHIC) — 95KB
- img59892534_13.jpg (GRAPHIC) — 243KB
- img59892534_14.jpg (GRAPHIC) — 239KB
- img59892534_15.jpg (GRAPHIC) — 119KB
- img59892534_16.jpg (GRAPHIC) — 150KB
- img59892534_17.jpg (GRAPHIC) — 269KB
- img59892534_18.jpg (GRAPHIC) — 276KB
- img59892534_19.jpg (GRAPHIC) — 297KB
- img59892534_20.jpg (GRAPHIC) — 245KB
- img59892534_21.jpg (GRAPHIC) — 194KB
- img59892534_22.jpg (GRAPHIC) — 153KB
- img59892534_23.jpg (GRAPHIC) — 94KB
- img59892534_24.jpg (GRAPHIC) — 284KB
- img59892534_25.jpg (GRAPHIC) — 140KB
- img59892534_26.jpg (GRAPHIC) — 376KB
- img59892534_27.jpg (GRAPHIC) — 137KB
- img59892534_28.jpg (GRAPHIC) — 264KB
- img59892534_29.jpg (GRAPHIC) — 254KB
- img59892534_30.jpg (GRAPHIC) — 260KB
- img59892534_31.jpg (GRAPHIC) — 114KB
- 0000950170-24-105585.txt ( ) — 16458KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NOVONIX LIMITED By: /s/ Dr. John Christopher Burns Dr. John Christopher Burns Chief Executive Officer Date: September 11, 2024